Review

.2018 Jun;32(2):253-268.

doi: 10.1016/j.idc.2018.02.002.

Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings

Anne C Moorman¹, Loralee B Rupp², Stuart C Gordon², Yuna Zhong³, Jian Xing³, Mei Lu⁴, Joseph A Boscarino⁵, Mark A Schmidt⁶, Yihe G Daida⁷, Eyasu H Teshale³, Philip R Spradling³, Scott D Holmberg³; CHeCS Investigators

Affiliations

¹ Division of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), Mailstop G-37, Atlanta, GA 30329, USA. Electronic address: Amoorman@cdc.gov.
² Division of Gastroenterology and Hepatology, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202, USA.
³ Division of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), Mailstop G-37, Atlanta, GA 30329, USA.
⁴ Public Health Sciences, Henry Ford Health System, 1 Ford Place -3A, Detroit, MI 48202, USA.
⁵ Department of Epidemiology and Health Services Research, Geisinger Clinic, 100 North Academy Avenue, Danville, PA 17822, USA.
⁶ Kaiser Permanente-Center for Health Research, Northwest, Kaiser Permanente Northwest, 3800 North Interstate Avenue, Portland, OR 97227-1098, USA.
⁷ Kaiser Permanente-Center for Health Research, Hawaii, Kaiser Permanente Hawaii, 501 Alakawa Street, Suite 201, Honolulu, HI 9681, USA.

PMID:29778254
PMCID: PMC6211170
DOI: 10.1016/j.idc.2018.02.002

Review

Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings

Anne C Moorman et al. Infect Dis Clin North Am.2018 Jun.

.2018 Jun;32(2):253-268.

doi: 10.1016/j.idc.2018.02.002.

Authors

Affiliations

¹ Division of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), Mailstop G-37, Atlanta, GA 30329, USA. Electronic address: Amoorman@cdc.gov.
² Division of Gastroenterology and Hepatology, Henry Ford Health System, 2799 West Grand Boulevard, Detroit, MI 48202, USA.
³ Division of Viral Hepatitis, Centers for Disease Control and Prevention (CDC), Mailstop G-37, Atlanta, GA 30329, USA.
⁴ Public Health Sciences, Henry Ford Health System, 1 Ford Place -3A, Detroit, MI 48202, USA.
⁵ Department of Epidemiology and Health Services Research, Geisinger Clinic, 100 North Academy Avenue, Danville, PA 17822, USA.
⁶ Kaiser Permanente-Center for Health Research, Northwest, Kaiser Permanente Northwest, 3800 North Interstate Avenue, Portland, OR 97227-1098, USA.
⁷ Kaiser Permanente-Center for Health Research, Hawaii, Kaiser Permanente Hawaii, 501 Alakawa Street, Suite 201, Honolulu, HI 9681, USA.

PMID:29778254
PMCID: PMC6211170
DOI: 10.1016/j.idc.2018.02.002

Abstract

Chronic Hepatitis Cohort Study (CHeCS) publications using data from "real-world" patients with hepatitis C virus (HCV) have described demographic disparities in access to care; rates of advanced liver disease, morbidity, and mortality (2.5%-3.5% per year during 2006-10, although only 19% of all CHeCS decedents, and just 30% of those with deaths attributed to liver disease, had HCV listed on death certificate); substantial comorbidities, such as diabetes, advanced liver fibrosis (29% prevalence), renal disease, and depression, and partial reversal of all these with successful antiviral therapy; patient risk behaviors; and use of noninvasive markers to assess liver disease.

Keywords: Cirrhosis; Comorbidities; Direct-acting antiviral; Hepatitis C; Mortality; Real-world cohort; Sustained viral response.

Published by Elsevier Inc.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have made the following disclosures: S.C. Gordon receives grant/research support from AbbVie Pharmaceuticals (M15–410, M13–576, M15–942, M14–222, M13–590, M14–227, M14–868), Conatus (IDN-6556–14, IDN-6556–120), CymaBay (CB8025–21629, CB8025–31731), Gilead Pharmaceuticals (GS-US-330–1508, GS-US-320–4018, GS-US-367–1170, GS-US-367–1171, GS-US-367–1172, GS-US-367–1173, GS-US-334–0154, GS-US-337–4063, IN-US-337–3957), Intercept Pharmaceuticals (747–303, 747–301, 747–302, 747–207, [Master agreement dated Nov 9, 2015, with Statements of Work 1–3 for Fibrotic Liver Diseases (FOLD) study]), and Merck (MK5172–017, MK5172–062, MK3682–035, MK3682–041, MK3682–012, MK3682–021). He is also a consultant/advisor for Abbvie, Gilead, Intercept, and Merck. L.B. Rupp, M. Lu, J.A. Boscarino, M.A. Schmidt, and Y.G. Daida receive research grant support from Gilead Pharmaceuticals (IN-US-337–3957) and Intercept (Master agreement dated Nov 9, 2015, with Statements of Work 1–3 for Fibrotic Liver Diseases (FOLD) study).

Cited by

Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation.
Crismale JF, Ahmad J.Crismale JF, et al.World J Gastroenterol. 2019 Dec 21;25(47):6799-6812. doi: 10.3748/wjg.v25.i47.6799.World J Gastroenterol. 2019.PMID:31885421Free PMC article.Review.
Annual trends of hepatitis C virus infection in Manitoba between 1998 and 2018: A focus on special populations.
Gudi SK, Eltonsy S, Delaney J, Osiowy C, Taylor C, Kaita K, Alessi-Severini S.Gudi SK, et al.Can Liver J. 2023 Jul 26;6(2):249-260. doi: 10.3138/canlivj-2022-0030. eCollection 2023 Jul.Can Liver J. 2023.PMID:37503521Free PMC article.
Trends in Indicators of Injection Drug Use, Indian Health Service, 2010-2014 : A Study of Health Care Encounter Data.
Evans ME, Person M, Reilley B, Leston J, Haverkate R, McCollum JT, Apostolou A, Bohm MK, Van Handel M, Bixler D, Mitsch AJ, Haberling DL, Hatcher SM, Weiser T, Elmore K, Teshale EH, Weidle PJ, Peters PJ, Buchacz K.Evans ME, et al.Public Health Rep. 2020 Jul/Aug;135(4):461-471. doi: 10.1177/0033354920937284. Epub 2020 Jul 7.Public Health Rep. 2020.PMID:32633599Free PMC article.
Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016.
Rosenberg ES, Rosenthal EM, Hall EW, Barker L, Hofmeister MG, Sullivan PS, Dietz P, Mermin J, Ryerson AB.Rosenberg ES, et al.JAMA Netw Open. 2018 Dec 7;1(8):e186371. doi: 10.1001/jamanetworkopen.2018.6371.JAMA Netw Open. 2018.PMID:30646319Free PMC article.
Testing for Hepatitis C Virus Infection Among Adults Aged ≥18 in the United States, 2013-2017.
King H, Soh JE, Thompson WW, Brown JR, Rapposelli K, Vellozzi C.King H, et al.Public Health Rep. 2022 Nov-Dec;137(6):1107-1117. doi: 10.1177/00333549211047236. Epub 2021 Oct 4.Public Health Rep. 2022.PMID:34606398Free PMC article.

See all "Cited by" articles

References

1. Moorman AC, Gordon SC, Rupp LR, et al. Baseline characteristics and mortality among people in care for chronic viral hepatitis: the Chronic Hepatitis Cohort Study (CHeCS). Clin Infect Dis 2013;56:40–50. - PubMed
1. Lu M, Rupp LB, Moorman AC, et al. Comparative effectiveness research of Chronic Hepatitis B and C Cohort Study (CHeCS): improving data collection and cohort identification. Dig Dis Sci 2014;59:3053–61. - PMC - PubMed
1. Abara WE, Moorman AC, Zhou Y, et al. The predictive value of International Classification of Disease Codes for chronic hepatitis C virus infection surveillance: the utility and limitations of electronic health records. Popul Health Manag. [Epub ahead of print]. - PMC - PubMed
1. Mahajan R, Moorman A, Liu S, et al. Use of the International Classification of Diseases, 9th revision, coding in identifying chronic hepatitis B virus infection in health system data: implications for national surveillance. J Am Med Inform Assoc 2013;20:441–5. - PMC - PubMed
1. Boscarino JA, Lu M, Moorman AC, et al. Predictors of poor mental and physical health status among patients with chronic hepatitis C infection: the Chronic Hepatitis Cohort Study (CHeCS). Hepatology 2015;61:802–11. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Movatterモバイル変換

Account

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Full text links

Actions

Share

Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings

Affiliations

Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical